During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic ...

Journal of Nuclear Medicine April 2025, jnumed.125.269670; DOI: https://doi.org/10.2967/jnumed.125.269670 ...

The current first-line treatment for peripheral T-cell lymphoma (PTCL) has a typically poor prognosis. Developing a new regimen is urgently needed. This phase I study evaluated the maximum tolerated ...

When facing a lymphoma diagnosis, understanding the available treatment options becomes crucial for patients navigating this challenging journey. Lymphoma, a cancer affecting the immune system’s ...

Memo del Bosque was diagnosed with Hodgkin’s lymphoma in 2017. This aggressive cancer primarily affects white blood cells Mexican television mourns the death of Guillermo “Memo” del Bosque ...

regimen for advanced stage classical Hodgkin lymphoma in a phase 3 trial. Although the patient backgrounds were different, both the BrECADD and eBEACOPP regimens in this study showed better outcomes ...

These findings suggest this unique cell therapy approach has promise for specific patients with lymphoma, but it may be adapted for more cancer types in the future. "We observed rapid and strong ...

Do CLL Alternative Therapies Work? Targeted drugs, surgery, and radiation are common treatments for chronic lymphocytic leukemia (CLL), but complementary therapy can also play a role in helping ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...